Internal Medicine · Los Angeles, CA
NPI
1992806277
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
4
Medicare group memberships
Hospitals
0
Hospital affiliations
1245 Wilshire Blvd, Ste 804
Los Angeles, CA, 90017
Phone (213) 977-1030
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.7M
264,109 services
Medicare patients, 2024
419
Average age 73
Drug cost, 2024
$5.6M
3,557 prescriptions
Company payments, 2025
$105K
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Soha Dolatabadi was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 100,403 times for 36 patients. In total Soha Dolatabadi billed 264,109 services in 40 codes, and Medicare paid $1.7M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-03-20.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 100,403 | 36 | $3.58 | $359K |
| J0174 Injection, lecanemab-irmb, 1 mg | Office | 76,800 | 13 | $1.05 | $80K |
| J1306 Injection, inclisiran, 1 mg | Office | 67,876 | 170 | $9.55 | $648K |
| J0897 Injection, denosumab, 1 mg | Office | 1,622 | 20 | $19.05 | $31K |
| 96372 Injection Administration | Office | 1,036 | 256 | $12.46 | $13K |
| 99214 Office E&M - Established | Office | 629 | 198 | $101.07 | $64K |
| 96365 Intravenous Infusion, Hydration | Office | 137 | 30 | $56.70 | $7,768 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 108 | 16 | $0.77 | $83.09 |
| 20611 Joint Injection | Office | 71 | 22 | $68.97 | $4,897 |
| 99204 Office E&M - New | Office | 58 | 58 | $121.44 | $7,044 |
| 96413 Chemotherapy Administration | Office | 32 | 14 | $94.61 | $3,028 |
| 99215 Office E&M - Established | Office | 14 | 14 | $125.94 | $1,763 |
| 99205 Office E&M - New | Office | 14 | 14 | $168.07 | $2,353 |
By year: 2022 $579K for 108,452 services; 2023 $539K for 112,917 services; 2024 $1.7M for 264,109 services.
Medicare prescription drug claims, 2024
In 2024, the drug Soha Dolatabadi prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 619 prescriptions and refills. In total Soha Dolatabadi wrote 3,557 Medicare prescriptions that cost $5.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 619 | 1,405 | 180 | $32K |
| Otrexup Methotrexate/Pf | 172 | 184 | 24 | $133K |
| Methotrexate Methotrexate Sodium | 154 | 288 | 37 | $3,860 |
| Leflunomide Generic | 152 | 354 | 53 | $17K |
| Rasuvo Methotrexate/Pf | 145 | 153 | 24 | $81K |
| Folic Acid Generic | 113 | 289 | 48 | $684 |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 108 | 238 | 38 | $1,038 |
| Prednisone Generic | 107 | 162 | 37 | $740 |
| Tramadol Hcl Generic | 95 | 102 | 36 | $358 |
| Benlysta Belimumab | 88 | 94 | 16 | $452K |
| Rinvoq Upadacitinib | 88 | 96 | 17 | $594K |
| Gabapentin Generic | 86 | 142 | 32 | $1,702 |
| Colchicine Generic | 77 | 162 | 30 | $7,147 |
| Celecoxib Generic | 74 | 98 | 20 | $1,217 |
| Duloxetine Hcl Generic | 71 | 152 | 23 | $2,971 |
Brand drugs: - claims; generic drugs: 2,395 claims; opioid claims: 117.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Soha Dolatabadi $105K ($105K in general payments such as food, travel and fees) from 20 companies. The largest payer was Janssen Biotech, Inc. with $31K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 56 | $31K |
| UCB, Inc. UCB.BR | 65 | $29K |
| Abbvie Inc. ABBV | 77 | $23K |
| GlaxoSmithKline, LLC. GSK | 21 | $9,646 |
| Novartis Pharmaceuticals Corporation NVS | 19 | $8,068 |
| Mallinckrodt Hospital Products Inc. | 14 | $1,582 |
| Amgen Inc. AMGN | 59 | $1,185 |
| Pfizer Inc. PFE | 10 | $277 |
| Lilly USA, LLC LLY | 9 | $238 |
| ANI Pharmaceuticals, Inc. ANIP | 9 | $187 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.